Genome Editing Market worth $11.2 billion by 2025

According to the new market research report "Genome Editing Market by Technology (CRISPR, TALEN, ZFN, Antisense), Product & Service, Application (Cell Line Engineering, Genetic Engineering, Diagnostics, Drug Discovery & Development), End-User and Region - Global Forecast to 2025", published by MarketsandMarkets™, the global Genome Engineering Market is projected to reach USD 11.2 billion in 2025 from USD 5.1 billion in 2020, at a CAGR of 17.0 % during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231037000

The market growth is largely driven by factors such as the rise in government funding, growth in the number of genomics projects, high prevalence of infectious diseases and cancer, technological advancements, increasing production of genetically modified crops, and growing application areas of genomics. However, the high cost of genomic equipment will restrain the growth of this market.

By technology, the CRISPR segment accounted for the largest share for the genome editing market.

The CRISPR technology segment accounted for the largest share of the genome editing/genome engineering industry in 2019. The large share of this segment can be attributed to the ease of use associated with CRISPR, which gives it a significant advantage over ZFN and TALEN. Another potential advantage is its ability to multiplex.

By end user, the pharmaceutical companies segment accounted for the largest share of the market.

Pharmaceutical companies accounted for the largest share of the genome engineering market, by end user, in 2019. The increasing prevalence of infectious diseases and cancer are driving research activities worldwide. This, in turn, is expected to drive the demand for genome editing in pharmaceutical companies.

By application, the cell line engineering segment accounted for the largest share of the market

Based on application, the genome editing market is segmented into cell line engineering, genetic engineering, diagnostic applications, drug discovery & development, and other applications. A number of factors, such as the increased funding from governments and private organizations, growing industry focus on stem cell research, and global awareness are driving market growth in this segment.

Request For Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=231037000

North America accounted for the largest share of the market.

The market is divided into four major regions—North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2019, North America accounted for the largest share of the global genome engineering market, closely followed by Europe. The large share of North America can be attributed to factors such as the development of gene therapy in the US, the increasing use of genetically modified crops, the rising prevalence of infectious diseases and cancer, and the availability of research grants and funding.

The market in the Asia Pacific is estimated to grow at the highest CAGR during the forecast period, primarily due to increasing investments in research and the application of gene synthesis for genetic engineering in cells, tissues, and organisms.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
sales@marketsandmarkets.com

Genome Engineering Market grow at a CAGR of 14.5% by 2022

According to research report the global Genome Engineering Market is expected to each to USD 6.28 Billion by 2022 from USD 3.19 Billion in 2017, at a CAGR of 14.5%. The key factors propelling the growth of this market are rising government funding and growth in the number of genomics projects, high prevalence of infectious diseases and cancer, technological advancements, increasing production of genetically modified crops, and growing application areas of genomics. Base year considered for the report is 2016 and the forecast period is 2017–2022.
Read More: https://www.marketsandmarkets.com/PressReleases/genome-editing-engineering.asp
CRISPR to account for the largest technology segment in the genome editing/genome engineering market in 2017
The technology segment of the genome editing market is classified into CRISPR, TALEN, ZFN, antisense, and other technologies (PiggyBac, Flp-In, Adenine Base Editor (ADE), and Jump-In). The CRISPR segment is expected to command the largest share of the global genome editing market in 2017. The large share of this segment can be attributed to the potential advantage of CRISPR is its ability to multiplex, that is, to use multiple guide RNAs in parallel to target multiple sites simultaneously in the same cell, making it easier to mutate multiple genes at once or engineer precise deletions in a genomic region.
Biotechnology & pharmaceutical companies to dominate the genome editing/genome engineering market during the forecast period
By end user, the genome editing market is segmented into biotechnology & pharmaceutical companies, academic & government research institutes, and contract research organizations. The biotechnology & pharmaceutical companies segment is estimated to account for the largest share of the global genome editing market in 2017. The increasing prevalence of infectious diseases and cancer are driving research activities worldwide; this is expected to drive the demand for genome editing in biotechnology & pharmaceutical companies.
Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231037000
In 2017, North America is expected to account for the largest share of the genome engineering market, followed by Europe. Factors such as the development of gene therapy in the US, increasing use of genetically modified crops, rising prevalence of infectious diseases and cancer, and rising availability of research grants and funding are propelling market growth in North America.
Factors such as dearth of skilled professionals and adverse public perception of genetic research are expected to limit the growth of the market to a certain extent. The prominent players include Thermo Fisher Scientific (US), Merck (Germany), Horizon Discovery Group (UK), GenScript (US), Sangamo BioSciences (US), Integrated DNA Technologies (US), Lonza Group (Switzerland), New England Biolabs (US), OriGene Technologies (US), Transposagen Biopharmaceuticals (US), Editas Medicine (US), and CRISPR Therapeutics (Switzerland).

Growth in the Genome Editing Market Is Likely To Be Focussed On the North America Region

According to research report the global Genome Engineering Market is projected to be valued at USD 3.19 Billion in 2017 and is expected to grow at a CAGR of 14.5% to reach to USD 6.28 Billion by 2022. Lucrative North America markets to offer significant growth opportunities for the genome editing market in the coming years. This can be attributed to the development of gene therapy, increasing use of genetically modified (GM) crops, and rising availability of research grants and funding in the U.S., and government initiatives and the intensification of genomics R&D in Canada.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=231037000  

Companies in the U.S. are developing their own gene therapies. For instance, in May 2015, Bluebird Bio began seeking approval for LentiGlobin, a gene therapy for beta-thalassemia, a blood disorder. These treatments are expected to be the first gene therapies approved in the U.S. Cold Genesys, Amgen, VBL Therapeutics, Advantagene, and UniQure are other companies developing gene therapies. Additionally, U.S. is the world’s largest producer of GM crops (Source: Worldwatch Institute). According to the Center for Food Safety (Washington, D.C.), in 2015, up to 92% of corn, 94% of soybeans, and 94% of cotton was genetically engineered (GE) in the U.S. Moreover, the adoption of herbicide-resistant corn has also grown significantly, reaching 89% in 2015 (Source: U.S. Department of Agriculture (USDA).

Government institutes like the CDC and the National Human Genome Research Institute (NHGRI) have provided funds and grants to support research in this field. For instance, in November 2014, the CDC funded USD 1.4 million to state health departments in Connecticut, Michigan, Oregon, and Utah to support cancer genomics for cancer diagnosis. Each department will receive USD 325,000 to 350,000 each year for five years (Source: CDC)

Furthermore, NHGRI also funds programs and projects as a part of its strategic plans. Some of the funded programs and projects including USD 1,000 Genome (for the structure of genomes), 1,000 Genomes Project (for the structure of genomes), and The Cancer Genome Atlas (TCGA) (for the biology of diseases. Industry players in the U.S. are focusing on collaboration, acquisition, partnerships, and agreements, among other strategies, to enhance their market shares. This has contributed directly to the overall development—and subsequently, the growth—of the U.S. market. For instance, in March 2016, Thermo Fisher (U.S.) acquired Affymetrix, Inc. (U.S.), a provider of technologies that enable multiplex and parallel analysis of biological systems at the cell, protein, and gene levels. The acquisition integrated Affymetrix’s major product groups into Thermo Fisher Scientific’s existing businesses.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231037000
The Canadian government has undertaken various initiatives to boost the gene engineering market in the country. In July 2016, Genome Canada funded genomic research projects across health, agriculture and agri-food, forestry, fisheries and aquaculture, environmental, energy, and mining, among other sectors. Additionally, Canada initiated a strategic plan towards funding genomics-based downstream research and development (R&D) projects. This includes the Genomic Applications Partnership Program (GAPP), initiated by the Ontario Genomics Institute (OGI). Furthermore, according to the Canadian Cancer Society, 196,900 new cancer cases were diagnosed in 2015, as opposed to 191,300 in 2014. Cancer is the largest cause of mortality in Canada, having caused 78,000 deaths in 2015—30% of the total deaths. The rising incidence of cancer, which will augment the need for diagnostic procedures, is likely to boost the growth of the genome editing market in Canada